{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 103,
  "pageCount": 366,
  "prevPage": 102,
  "nextPage": 104,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide presents two distinct expert critiques regarding IP expiration and clinical trial quality, attributed to a senior scientist at Johnson & Johnson.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/103",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-103",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.37
      },
      "kind": "callout",
      "text": "No intellectual property as pitolisant is an ancient compound dating back to 1999 or earlier",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b87b5d3-2ea2-433e-95e7-05cd74456f5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.86,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "callout",
      "text": "Prader Wills study is anecdotal and irrelevant; pharma companies dismissive of H3; “better compounds out there that are probably safer” than pitolisant",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3a03e60-119e-4199-9d77-5a12f7f9f77e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "there are far better H3 antagonists out there if this works. So, if an H3 antagonist works with Prader-Willi, then there are better compounds out there that are probably safer.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd1-4756c4cb2042",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "He expressed other criticism of pitolisant, stating that the compound was so old – dating back perhaps to 1999 or earlier – that it couldn’t have any intellectual property left. In addition, he was familiar with Harmony’s recent phase 2 data for sleepiness in Prader-Willi syndrome, and indicated it was anecdotal and lacked credibility: “there are far better H3 antagonists out there if this works. So, if an H3 antagonist works with Prader-Willi, then there are better compounds out there that are probably safer. I got the impression, too, a lot of pharmaceutical companies thought H3 was a target in search of a disease.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe618a4c-2874-479d-a6ef-6c75467ee1f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.67
      },
      "kind": "quote",
      "text": "“I've seen clinical trial results geography-dependent. I did a meeting in Poland last month where I saw a presentation on Wakix. And Wakix has been picked up by—is being used by a charitable group in the United States that are focused on Prader-Willi Syndrome. My recollection, though, is that it was anecdotal data. They spoke to the patients, and I saw some videos of the patients, and they seemed better. But it was all anecdotal. I don't think—I'm not sure the patient population is big enough for it to demonstrate a statistical significance, actually. But that's where they're going, and they got this charitable foundation, I think, to work with them. And I remember saying to the guy that presented, I said there are far better H3 antagonists out there if this works. So, if an H3 antagonist works with Prader-Willi, then there are better compounds out there that are probably safer. I got the impression, too, a lot of pharmaceutical companies thought H3 was a target in search of a disease.” –Longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7646ce0e-d0bb-4511-9a37-b9f5e4ee9caf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "quote",
      "text": "A: “The other thing about that compound is I don't know how strong the intellectual property is. I'm assuming you've looked at that.” Q: “It's one of the things I need to get to. But the thing is so old.” A: “It's got to be. My recollection is I saw applications from Jean-Charles Schwartz, from Walter Schnunack, and all these old guys—Walter is actually dead now—they had huge patent applications that they filed. But I don't know—I'm not an attorney. I think that compound was out there in 1999. So, that's a long time ago. So, if they got any patent life, I don't think it can be very much.” –Longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f791af3d-4396-4f61-9a6a-ed2a8f730bf6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“there are far better H3 antagonists out there if this works. So, if an H3 antagonist works with Prader-Willi, then there are better compounds out there that are probably safer. I got the impression, too, a lot of pharmaceutical companies thought H3 was a target in search of a disease.” — Longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd1-4b41ce0649c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d65d8de-d6bc-4afc-bf4b-078736ce26fe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}